Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus

The Department of Internal Medicine, Diabetology and Endocrinology Division, Mie University School of Medicine, Japan.

OBJECTIVE: To investigate the relationship between the circulating level of active ghrelin and abdominal adiposity, serum levels of insulin or insulin resistance in patients with type 2 diabetes mellitus. DESIGN: We measured the plasma levels of the active form of ghrelin in 18 obese and 18 nonobese patients with type 2 diabetes mellitus using a radioimmunoassay (RIA) kit. Body fat accumulation was measured by computed tomography (CT) and insulin resistance by the glucose infusion rate (GIR) during an euglycemic hyperinsulinemic clamp study. RESULTS: Plasma levels of ghrelin in obese patients with type 2 diabetes mellitus were significantly decreased compared with nonobese patients. There were significant correlations between the plasma levels of ghrelin and BMI (r=-0.505, P<0.01), visceral (r=-0.444, P<0.01), subcutaneous (r=-0.506, P<0.01) and total (r=-0.534, P<0.01) fat area, serum levels of insulin (r=-0.513, P<0.01) or GIR (r=0.478, P<0.01) in type 2 diabetic patients. The plasma level of ghrelin was significantly associated with serum levels of insulin (F=8.468, P<0.05) or GIR (F=8.522, P<0.05) after adjustment for BMI in patients with type 2 diabetes mellitus. CONCLUSIONS: Decreased plasma levels of active ghrelin are significantly associated with abdominal adiposity, hyperinsulinemia and insulin resistance in type 2 diabetic patients. Hyperinsulinemia associated with insulin resistance may suppress plasma levels of active ghrelin in patients with type 2 diabetes mellitus.

This article has been cited by other articles:

				E Sondergaard, L C Gormsen, B Nellemann, E T Vestergaard, J S Christiansen, and S Nielsen Visceral fat mass is a strong predictor of circulating ghrelin levels in premenopausal women Eur. J. Endocrinol., March 1, 2009; 160(3): 375 - 379. [Abstract] [Full Text] [PDF]

				E. Ingelsson, M. G. Larson, X. Yin, T. J. Wang, J. B. Meigs, I. Lipinska, E. J. Benjamin, J. F. Keaney Jr., and R. S. Vasan Circulating Ghrelin, Leptin, and Soluble Leptin Receptor Concentrations and Cardiometabolic Risk Factors in a Community-Based Sample J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3149 - 3157. [Abstract] [Full Text] [PDF]

				U. Mager, M. Kolehmainen, V. D F de Mello, U. Schwab, D. E Laaksonen, R. Rauramaa, H. Gylling, M. Atalay, L. Pulkkinen, and M. Uusitupa Expression of ghrelin gene in peripheral blood mononuclear cells and plasma ghrelin concentrations in patients with metabolic syndrome. Eur. J. Endocrinol., April 1, 2008; 158(4): 499 - 510. [Abstract] [Full Text] [PDF]

				T. M Barber, F. F Casanueva, F. Karpe, M. Lage, S. Franks, M. I McCarthy, and J. A H Wass Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur. J. Endocrinol., April 1, 2008; 158(4): 511 - 516. [Abstract] [Full Text] [PDF]

				M. Anderwald-Stadler, M. Krebs, M. Promintzer, M. Mandl, M. G. Bischof, P. Nowotny, T. Kastenbauer, A. Luger, R. Prager, and C. Anderwald Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans Am J Physiol Endocrinol Metab, November 1, 2007; 293(5): E1393 - E1398. [Abstract] [Full Text] [PDF]

				X. Wang, L. Liang, and L. Du The effects of intrauterine undernutrition on pancreas ghrelin and insulin expression in neonate rats J. Endocrinol., July 1, 2007; 194(1): 121 - 129. [Abstract] [Full Text] [PDF]

				A Majuri, M Santaniemi, K Rautio, A Kunnari, J Vartiainen, A Ruokonen, Y A Kesaniemi, J S Tapanainen, O Ukkola, and L Morin-Papunen Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study Eur. J. Endocrinol., February 1, 2007; 156(2): 263 - 269. [Abstract] [Full Text] [PDF]

				F. Bacha and S. A. Arslanian Ghrelin and Peptide YY in Youth: Are There Race-Related Differences? J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 3117 - 3122. [Abstract] [Full Text] [PDF]

				C. Langenberg, J. Bergstrom, G. A. Laughlin, and E. Barrett-Connor Ghrelin and the Metabolic Syndrome in Older Adults J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6448 - 6453. [Abstract] [Full Text] [PDF]

				E T Vestergaard, T K Hansen, S Nielsen, N Moller, J S Christiansen, and J O L Jorgensen Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis Eur. J. Endocrinol., October 1, 2005; 153(4): 545 - 549. [Abstract] [Full Text] [PDF]

				M. Suematsu, A. Katsuki, Y. Sumida, E. C Gabazza, S. Murashima, K. Matsumoto, N. Kitagawa, H. Akatsuka, Y. Hori, K. Nakatani, et al. Decreased circulating levels of active ghrelin are associated with increased oxidative stress in obese subjects Eur. J. Endocrinol., September 1, 2005; 153(3): 403 - 407. [Abstract] [Full Text] [PDF]